Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease that
affects approximately one-quarter of the global adult population, posing a significant threat …

The global prevalence of non‐alcoholic fatty liver disease (NAFLD) is rising, along with the
epidemic of diabesity. NAFLD is present in> 70% of individuals with type 2 diabetes …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
affecting approximately 25% of the general population worldwide, and is forecasted to …

The burden of HCC is substantial. To address gaps in HCC care, the American Association
for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) aimed to …

Context Metabolic associated fatty liver disease (MAFLD) is the hepatic manifestation of
obesity-related metabolic syndrome (MetS). Noninvasive biomarkers for monitoring the …

Abstract Background Circulating thrombospondin-2 (TSP2) levels were associated with the
development of heart failure (HF) in recent studies. However, these studies included only a …

BACKGROUND: The circulating proteome may encode early pathways of diabetes
susceptibility in young adults for surveillance and intervention. Here, we define proteomic …

Objective. The aim of this study is to assess the relationship between T‐lymphocyte subsets,
regulatory T cells (Treg), and hepatic fibrosis in patients with a nonalcoholic fatty liver …

Aortic valve degeneration (AVD) is a life-threatening condition that has no medical treatment
and lacks individual therapies. Although extensively studied with standard approaches …

Simple Summary Secreted glycoprotein thrombospondin-2 (TSP-2) is a predictive biomarker
of hepatocellular carcinoma (HCC) occurrence in chronic hepatitis C (CHC) patients after …